Upgrade to SI Premium - Free Trial

Genmab A/S (GMAB)

33.60 -0.81 (2.35%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (11/5/26)

Latest Headlines

BofA Securities Reiterates Buy Rating on Genmab A/S (GEN:DC) (GMAB) September 4, 2026 6:06 AM - StreetInsider Genmab A/S (GEN:DC) (GMAB) PT Raised to DKK2,500 at Deutsche Bank September 1, 2026 4:44 AM - StreetInsider Form SCHEDULE 13G/A GENMAB A/S Filed by: ORBIS INVESTMENT MANAGEMENT LTD August 14, 2026 1:15 PM - SEC Filing Form 6-K GENMAB A/S For: Aug 12 August 12, 2026 9:49 AM - SEC Filing Form 6-K GENMAB A/S For: Aug 11 August 11, 2026 2:15 PM - SEC Filing Capital Increase in Genmab as a Result of Employee Warrant Exercise August 11, 2026 1:54 PM - StreetInsider Genmab A/S (GEN:DC) (GMAB) PT Raised to DKK2,700 at UBS August 7, 2026 4:37 AM - StreetInsider Genmab stock falls despite H1 revenue rise August 6, 2026 1:20 PM - StreetInsider Form 6-K GENMAB A/S For: Jun 30 August 6, 2026 11:09 AM - SEC Filing Genmab revenue rises 25% in first half of 2026, guidance raised August 6, 2026 11:02 AM - StreetInsider Genmab Announces Financial Results for the First Half of 2026 August 6, 2026 11:01 AM - Globe NewsWire Genmab and AbbVie say epcoritamab trial missed U.S. survival goal July 23, 2026 4:00 PM - StreetInsider Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) July 23, 2026 4:00 PM - StreetInsider TD Cowen Upgrades Genmab A/S (GMAB) to Buy July 22, 2026 6:15 AM - StreetInsider Form 6-K GENMAB A/S For: Jul 15 July 15, 2026 7:22 AM - SEC Filing Darzalex global sales reach $4.2 billion in Q2 2026 July 15, 2026 6:23 AM - StreetInsider Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2026 July 15, 2026 6:22 AM - Globe NewsWire H.C. Wainwright Reiterates Buy Rating on Genmab A/S (GMAB) July 13, 2026 6:36 AM - StreetInsider Genmab A/S (GEN:DC) (GMAB) PT Raised to DKK2,800 at Jefferies July 7, 2026 7:49 AM - StreetInsider EU approves Genmab's Tepkinly combo for relapsed follicular lymphoma July 6, 2026 1:45 PM - StreetInsider Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma July 6, 2026 1:45 PM - BizWire Genmab A/S (GMAB) PT Raised to $40 at H.C. Wainwright July 2, 2026 6:41 AM - StreetInsider William Blair Adjusts Monthly Analyst Conviction List for July 2026 July 1, 2026 6:19 AM - StreetInsider Form 6-K GENMAB A/S For: Jun 29 June 29, 2026 4:24 PM - SEC Filing Genmab's epcoritamab combo cuts lymphoma progression risk by 60% June 29, 2026 4:14 PM - StreetInsider Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in P June 29, 2026 4:14 PM - StreetInsider Form 6-K GENMAB A/S For: Jun 17 June 17, 2026 11:30 AM - SEC Filing Form 6-K GENMAB A/S For: Jun 16 June 16, 2026 3:37 PM - SEC Filing Capital Increase in Genmab as a Result of Employee Warrant Exercise June 16, 2026 3:13 PM - StreetInsider Form 6-K GENMAB A/S For: Jun 15 June 15, 2026 12:09 PM - SEC Filing Major Shareholder Announcement June 15, 2026 12:04 PM - Globe NewsWire Form 6-K GENMAB A/S For: Jun 15 June 15, 2026 11:08 AM - SEC Filing Form 6-K GENMAB A/S For: Jun 11 June 11, 2026 1:58 PM - SEC Filing Grant of Restricted Stock Units and Warrants to Employees in Genmab June 11, 2026 1:17 PM - StreetInsider Genmab presents positive EPCORE FL-1 subgroup data for lymphoma treatment June 11, 2026 10:46 AM - StreetInsider Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R²) Across Relapsed or Refractory (R/R June 11, 2026 10:45 AM - BizWire Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R June 11, 2026 10:45 AM - StreetInsider Full Article List